Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) shares gapped up prior to trading on Monday. The stock had previously closed at $14.95, but opened at $16.00. Ono Pharmaceutical shares last traded at $16.00, with a volume of 192 shares traded.
Wall Street Analyst Weigh In
Separately, Zacks Research lowered shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
View Our Latest Research Report on OPHLF
Ono Pharmaceutical Stock Performance
The firm has a fifty day moving average price of $15.13 and a two-hundred day moving average price of $14.70. The stock has a market capitalization of $7.52 billion, a PE ratio of 15.24 and a beta of 0.38. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.28 and a quick ratio of 2.86.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.
Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
- Insiders Are Selling These 5 AI Stocks—Should You Worry?
- 3 Companies With Room to Pass on Costs to Manage Inflation
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
